News

Bio Pharma APAC
biopharmaapac. com > news > 83 > 8130 > samsung-biologics-accelerates-sustainability-strategy-with-stronger-esg-performance. html

Samsung Biologics Accelerates Sustainability Strategy with Stronger ESG Performance

13+ hour, 25+ min ago  (503+ words) Bio Pharma APAC - Samsung Biologics Accelerates Sustainability Strategy with Stronger ESG Performance 02 July 2026 | Thursday | News - Advanced environmental performance through renewable energy transition and enhanced carbon transparency - Strengthened sustainability management and supply chain engagement across the healthcare value chain Samsung Biologics…...

Symbols: 207940.ks
Bio Pharma APAC
biopharmaapac. com > analysis > 16 > 8136 > vectors-plasmids-and-the-cgt-trap-apacs-cell-and-gene-therapy-ambitions-face-an-upstream-bottleneck. html

Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck

7+ hour, 24+ min ago  (236+ words) 02 July 2026 | Thursday | Analysis The choke point nobody puts on the slide Secure the vector and you have a medicine. Miss the slot and you have a slide. Capacity, cost and the comparability trap Make, buy, or vertically integrate This is…...

Symbols: btc-usd
Bio Pharma APAC
biopharmaapac. com > news > 125 > 8129 > basf-and-bota-biosciences-launch-ai-developed-recombinant-collagen-ingredient-for-premium-skincare. html

BASF and Bota Biosciences Launch AI-Developed Recombinant Collagen Ingredient for Premium Skincare

13+ hour, 25+ min ago  (405+ words) Bio Pharma APAC - BASF and Bota Biosciences Launch AI-Developed Recombinant Collagen Ingredient for Premium Skincare 02 July 2026 | Thursday | News Bota Biosciences and BASF jointly announced the market launch of BASF's Skin Nexus" Collag3n. This 100% human-identical recombinant Collagen III fragment was developed in…...

Symbols: btc-usd
Bio Pharma APAC
biopharmaapac. com > news > 32 > 8131 > metis-techbio-signs-us1-62-billion-licensing-deal-for-ai-designed-cancer-therapy-with-boulevard-bio. html

METi S Tech Bio Signs US$1. 62 Billion Licensing Deal for AI-Designed Cancer Therapy with Boulevard Bio

13+ hour, 27+ min ago  (684+ words) Bio Pharma APAC - METi S Tech Bio Signs US$1. 62 Billion Licensing Deal for AI-Designed Cancer Therapy with Boulevard Bio 02 July 2026 | Thursday | News METi S Tech Bio (7666. HK), a leading AI-driven drug delivery innovation company, announced it has entered into an…...

Symbols: nasdaq:gtbp
Bio Pharma APAC
biopharmaapac. com > news > 16 > 8124 > pharmaresearch-expands-u-s-footprint-with-cg-usa-acquisition-to-boost-rejuran-cosmetics-growth. html

Pharma Research Expands U. S. Footprint with CG USA Acquisition to Boost REJURAN Cosmetics Growth

13+ hour, 24+ min ago  (159+ words) 01 July 2026 | Wednesday | News Pharma Research'signed an agreement on June 30, local time, to'acquire'CG USA, a cosmetics OEM and ODM manufacturer, as demand for REJURAN Cosmetics continues to grow in the United States.' Building on this, the company plans to strengthen supply…...

Symbols: btc-usd
Bio Pharma APAC
biopharmaapac. com > news > 32 > 8126 > inductive-bio-brings-ai-powered-admet-prediction-models-to-claude-via-new-mcp-connector. html

Inductive Bio Brings AI-Powered ADMET Prediction Models to Claude via New MCP Connector

13+ hour, 27+ min ago  (446+ words) Bio Pharma APAC - Inductive Bio Brings AI-Powered ADMET Prediction Models to Claude via New MCP Connector 02 July 2026 | Thursday | News Inductive Bio, an AI drug discovery partner developing virtual chemistry labs, announced that it has joined Anthropic's life sciences ecosystem and…...

Symbols: btc-usd
Bio Pharma APAC
biopharmaapac. com > news > 89 > 8127 > alr-technologies-expands-diabetes-device-business-with-cgm-medical-acquisition. html

ALR Technologies Expands Diabetes Device Business with CGM Medical Acquisition

1+ day, 7+ hour ago  (739+ words) Bio Pharma APAC - ALR Technologies Expands Diabetes Device Business with CGM Medical Acquisition 01 July 2026 | Wednesday | News ALR Technologies SG Ltd ("ALRT" or the "Company") (OTC: ALRTF), the diabetes management company, announces it has entered into a Letter of Intent ("LOI…...

Symbols: nasdaq:dxcm
Bio Pharma APAC
biopharmaapac. com > news > 81 > 8125 > colossal-foundation-and-university-of-tasmania-partner-to-fight-deadly-tasmanian-devil-cancer-with-gene-editing-and-vaccines. html

Colossal Foundation and University of Tasmania Partner to Fight Deadly Tasmanian Devil Cancer with Gene Editing and Vaccines

1+ day, 7+ hour ago  (299+ words) 01 July 2026 | Wednesday | News The collaboration leverages Colossal's marsupial de-extinction and conservation biotechnology platform to save the Tasmanian devil from a contagious cancer that has driven 80% population declines across Tasmania The Colossal Foundation, the nonprofit conservation arm of Colossal Biosciences," announced…...

Symbols: nasdaq:gtbp,nasdaq:fate,nasdaq:nktx,btc-usd
Bio Pharma APAC
biopharmaapac. com > analysis > 120 > 8123 > can-apac-build-radioligand-therapy-before-the-atoms-decay. html

Can APAC Build Radioligand Therapy Before the Atoms Decay?

1+ day, 9+ hour ago  (268+ words) 01 July 2026 | Wednesday | Analysis The Isotope Clock: Supply & Decay at a Glance Half-life ~6. 6 days. Made by irradiating ytterbium-176 targets in high-flux research reactors, then chemically separated into high-purity "no-carrier-added" material over several days. The workhorse behind Lutathera and Pluvicto; roughly 29% of…...

Symbols: non-ce
Bio Pharma APAC
biopharmaapac. com > news > 69 > 8119 > icosagen-completes-45-million-expansion-to-deliver-end-to-end-biologics-development-and-gmp-manufacturing-at-a-single-site. html

Icosagen Completes "45 Million Expansion to Deliver End-to-End Biologics Development and GMP Manufacturing at a Single Site

1+ day, 18+ hour ago  (235+ words) 01 July 2026 | Wednesday | News Supported by an "18 million loan from the European Investment Bank (EIB), backed by the Invest EU program, and combined with Icosagen's own funding, the initiative represents a total investment of "45 million. The program included the establishment of…...

Symbols: nasdaq:ppcb